<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ910626-0134</DOCNO><DOCID>910626-0134.</DOCID><HL>   Technology:   Synergen, NYU Obtain Patent</HL><DATE>06/26/91</DATE><SO>WALL STREET JOURNAL (J), PAGE C8</SO><CO>   SYGN SYN</CO><MS>CONSUMER NON-CYCLICAL (NCY)TECHNOLOGY (TEC)</MS><IN>DRUG MANUFACTURERS (DRG)MEDICAL AND BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)</IN><RE>CALIFORNIA (CA)COLORADO (CO)NORTH AMERICA (NME)NEW YORK (NY)PACIFIC RIM (PRM)UNITED STATES (US)</RE><LP>   BOULDER, Colo. -- Synergen Inc. and New York UniversityMedical Center said they obtained their second patent relatedto their human basic fibroblast growth factor, a humangrowth-promoting protein.   The recently awarded patent covers the DNA sequence forthe protein.</LP><TEXT>   Synergen, a biotechnology company, and NYU Medical Centerjointly own the patent. They received a patent on the proteinitself in February.   Synergen is developing the use of the basic fibroblastgrowth factor under the name Trofak as a treatment forchronic skin ulcers. The company also has a joint venturewith Syntex Inc., Palo Alto, Calif., to develop the proteinto treat neurological diseases such as Alzheimer's andParkinson's disease.</TEXT></DOC>